Saturday, March 12, 2022

Watch Rollout of Our Mega Moon Rocket

NASA EMAIL:

The launch of our uncrewed Artemis I Moon mission is fast approaching, and we’re inviting you to join us for the final test before liftoff.  

Starting March 17, our teams will roll the 322-foot-tall Space Launch System rocket and Orion spacecraft out of the Vehicle Assembly Building (VAB) at NASA’s Kennedy Space Center in Florida and onto the launchpad for the first time. 

The rollout involves placing the entire integrated launch system atop a crawler-transporter, which will traverse the 4-mile distance between the VAB and Launch Complex 39B in a journey that is expected to take somewhere between six and 12 hours. Approximately two weeks after arrival at 39B, our launch teams will conduct a “wet dress rehearsal”, a final prelaunch test that includes loading the large, central core stage of the rocket with liquid oxygen and liquid hydrogen – that’s the “wet” part – and a mock countdown to launch. 

Join us for a live broadcast of the rollout starting at 5 p.m. EDT on March 17, which will include live remarks from NASA Administrator Bill Nelson and other guests. Coverage will air on NASA Television, the NASA app, and our official social media channels. 

PLUS: Is wet-dress whetting your appetite for launch? Register to be a NASA virtual guest for the launch of Artemis I and get curated resources, interaction opportunities, schedule changes, and mission-specific information straight to your inbox. Following the launch, virtual guests will be sent a stamp for their virtual guest passports! 


Must Wach BloggerPride Video:

Wednesday, March 9, 2022

你喜欢印度菜吗?인도 음식을 좋아하세요? あなたはインド料理が好きですか

 你喜欢印度菜吗?您想观看印度美食的视频吗?请订阅 BloggerPride YouTube 频道。.


인도 음식을 좋아하세요? 인도 음식의 영상을 보고 싶으세요? BloggerPride YouTube 채널을 구독하십시오.

あなたはインド料理が好きですか?インド料理のビデオを見たいですか? BloggerPrideYouTubeチャンネルに登録してください。

WHO issues new guidelines on abortion to help countries deliver lifesaving care

GENEVA, March 9th, 2022 -- The World Health Organization (WHO) is releasing new guidelines on abortion care today, in a bid to protect the health of women and girls and help prevent over 25 million unsafe abortions that currently occur each year.

“Being able to obtain a safe abortion is a crucial part of health care,” said Craig Lissner, acting Director for Sexual and Reproductive Health and Research at WHO. “Nearly every death and injury that results from unsafe abortion is entirely preventable. That’s why we recommend women and girls can access abortion and family planning services when they need them.”

Based on the latest scientific evidence, these consolidated guidelines bring together over 50 recommendations spanning clinical practice, health service delivery, and legal and policy interventions to support quality abortion care.

New recommendations to improve access to high quality, person-centered services

When abortion is carried out using a method recommended by WHO, appropriate to the duration of the pregnancy, and assisted by someone with the necessary information or skills, it is a simple and extremely safe procedure.

Tragically, however, only around half of all abortions take place under such conditions, with unsafe abortions causing around 39,000 deaths every year and resulting in millions more women hospitalized with complications. Most of these deaths are concentrated in lower-income countries – with over 60 percent in Africa and 30 percent in Asia - and among those living in the most vulnerable situations.

The guideline includes recommendations on many simple primary care level interventions that improve the quality of abortion care provided to women and girls. These include task sharing by a wider range of health workers; ensuring access to medical abortion pills, which means more women can obtain safe abortion services, and making sure that accurate information on care is available to all those who need it.

For the first time, the guidelines also include recommendations for use where appropriate of telemedicine, which helped support access to abortion and family planning services during the COVID-19 pandemic.

Removing unnecessary policy barriers facilitates safe abortion access

Alongside the clinical and service delivery recommendations, the guidelines recommend removing medically unnecessary policy barriers to safe abortion, such as criminalization, mandatory waiting times, the requirement that approval must be given by other people (e.g., partners or family members) or institutions, and limits on when during pregnancy an abortion can take place. Such barriers can lead to critical delays in accessing treatment and put women and girls at greater risk of unsafe abortion, stigmatization, and health complications while increasing disruptions to education and their ability to work.

While most countries permit abortion under specified circumstances, about 20 countries provide no legal grounds for abortion. More than 3 in 4 countries have legal penalties for abortion, which can include lengthy prison sentences or heavy fines for people having or assisting with the procedure.

“It’s vital that an abortion is safe in medical terms,” said Dr. Bela Ganatra, Head of WHO’s Prevention of Unsafe Abortion Unit. “But that’s not enough on its own. As with any other health services, abortion care needs to respect the decisions and needs of women and girls, ensuring that they are treated with dignity and without stigma or judgment. No one should be exposed to abuse or harms like being reported to the police or put in jail because they have sought or provided abortion care."

Evidence shows that restricting access to abortions does not reduce the number of abortions that take place. In fact, restrictions are more likely to drive women and girls towards unsafe procedures. In countries where abortion is most restricted, only 1 in 4 abortions is safe, compared to nearly 9 in 10 in countries where the procedure is broadly legal.

“The evidence is clear – if you want to prevent unintended pregnancies and unsafe abortions, you need to provide women and girls with a comprehensive package of sexuality education, accurate family planning information and services, and access to quality abortion care,” Dr. Ganatra added.

Following the launch of the guidelines, WHO will support interested countries to implement these new guidelines and strengthen national policies and programs related to contraception, family planning, and abortion services, helping them provide the highest standard of care for women and girls.

#Motherhood - Mata Sahib Kaur Ji #shorts #Punjabi #animatedmovie





Saturday, March 5, 2022

Fly Your Name Around The Moon with #nasa #artemis #moon #shorts Get Boarding pass


Fly Your Name Around The Moon with #NASA Rocket #Artemis #moon #orbit #shorts चाँद के चक्कर लगाते हुए नासा के राकेट में आपका नाम भी चाँद के चक्कर लगा सकता है. Get your Boarding pass now: youtu.be/jvrBJ4PN5Qk

Thursday, March 3, 2022

Alfredo Pasta & peri peri fries #shorts #alfredopasta #periperifries #streetfood

Amazing Gud making from Sugar cane juice #shorts #trending #viral #viralvideo #viralshorts #गुड़

Blueberry Cake Cutting #shorts #blueberrycake #cake #cakes

DSGMC to send a 20-members delegation to help the stranded Indian students in Ukraine

New Delhi, March 3,  Harmeet Singh Kalka, President, and Jagdip Singh Kahlon, General Secretary, Delhi Sikh Gurdwara Management Committee (DSGMC) has informed the media that Delhi Sikh Committee will send a 20-member delegation to help the stranded people in Ukraine. The delegation will comprise of senior members, staff, and volunteers. 


The delegation will be divided into two parts- one part will visit the border of Poland and the other will visit Slovakia to help the stranded people there.  Special camps will be organized there to distribute langar, medical assistance and extend all possible assistance to the stranded people on humanitarian grounds. They said after the war, the situation gets worsened and people need much more assistance. DSGMC deems its duty to send the delegation to serve the people in distress. 

Kalka and Kahlon further said that DSGMC stands at the forefront to provide its services to needy people at the time of natural calamities. In the past, DSGMC has done commendable service whenever the country needed for example at the time of natural calamities in Uttrakhand, Gujarat, Kashmir, Uttar Pradesh, Punjab and in Nepal and other places in abroad. The motto of the DSGMC is to serve humanity following the teachings of our Guru Sahibs

WHO updates its treatment guidelines to include molnupiravir

This ninth update of WHO’s guideline on therapeutics includes a recommendation that casirivimab-imdevimab not be used for patients infected with the Omicron variant



Geneva, 3 March 2022 | WHO has updated its living guidelines on COVID-19 therapeutics to include a conditional recommendation on molnupiravir, a new antiviral medicine.

This is the first oral antiviral drug to be included in the treatment guidelines for COVID-19. As this is a new medicine, there is little safety data. WHO recommends active monitoring for drug safety, along with other strategies to mitigate potential harms.

Because of these concerns and data gaps, molnupiravir should be provided only to non-severe COVID-19 patients with the highest risk of hospitalization. These are typically people who have not received a COVID-19 vaccination, older people, people with immunodeficiencies and people living with chronic diseases.

Children, and pregnant and breastfeeding women should not be given the drug. People who take molnupiravir should have a contraceptive plan, and health systems should ensure access to pregnancy testing and contraceptives at the point of care.

Under the care of a health care provider, molnupiravir, an oral tablet, is given as four tablets (total 800 mg) twice daily for five days; within 5 days of symptom onset. Used as early as possible after infection, it can help prevent hospitalization.

Today’s recommendation is based on new data from six randomized controlled trials involving 4,796 patients. This is the largest dataset on this drug so far.

Along with a recommendation on molnupiravir, this ninth update of WHO’s living guideline on therapeutics includes an update on casirivimab-imdevimab, a monoclonal antibody cocktail. Based on evidence that this combination of drugs is ineffective against the Omicron variant of concern, WHO now recommends that it is only given when the infection is caused by another variant.

Molnupiravir is not widely available but steps have been taken towards increasing access, including the signing of a voluntary licensing agreement. The Access to COVID-19 Tools Accelerator (ACT-A) is making a limited supply available to countries with access constraints.

WHO has also invited manufacturers to submit their products for prequalification, with a number of manufacturers of molnupiravir going through assessment now. WHO evaluates the quality, safety and efficacy of medical products for United Nations and other large suppliers to low- and middle-income countries. More WHO quality-assured manufacturers mean that countries have a greater choice of products and more competitive prices.  

Thanks: WHO